Exclusive Investor Insights: Listen to Zack Bozinovski from Wellnex Life (ASX:WNX) as he discusses key investor highlights, covering the acquisition of PainAway, JV with Chemist Warehouse, global partnership with Haleon and the company strategy over the next 6 to 12 months as they are currently raising capital.

For more information on the investment opportunity, please contact Michael Jeffery or James Whelan.

Read the Conversation:

I'm here with Zack Bozinovski, the Managing Director of Wellnex Life. The company develops innovative pharmaceutical brands and intellectual property to improve health. They are currently raising capital to grow their presence in the pharmaceutical market. Zack, what are the three key points you would like the market to know about Wellnex?

What's important to understand about our company is the evolution of our company, uh, into a branded business, which has its own IP, which we can drive additional sales revenue within the market. Probably the second point is, and very importantly for us at the moment, is we're in the middle of a capital raise for the acquisition of a company called PainAway.

Um, PainAway will deliver additional revenue. profitability, but more importantly, we'll integrate seamlessly into the Wellnex business, um, to give us further growth and profitability moving forward. And I think the final point is, is that we're all about that continued innovation and IP development. Um, you know, we really spend a lot of time understanding what's happening overseas markets.

Talking to our retail partners here in both the grocery and pharmacy and then aligning on what um, direction these categories are going in and uh, ensuring that we develop products to align with that growth strategy. Thanks, Zack. That was a great insight. To help investors understand Wellnex at a holistic level, can you please outline the strategy over the next 6 to 12 months?

Yeah, we, we're on a, um, on a very strong growth path with, uh, all of the products we've launched over the last 2 years. So over the last 2 years we've launched, uh, 6 brands, um, we've been involved in, uh, joint ventures. Uh, with companies like Chemist Warehouse and most importantly, and something that I'm very proud of the company is we have a global partnership with Haleon, which was XGSK for their Panadol Paracetamol brand, and they utilize our IP for paracetamol in their brand and yeah, that is a really strong testament to what this company is about is the innovation, which I mentioned before, and the development and having major multinationals utilizing our products in their brands. I think the other part of where we're going is the acquisition of PainAway.

Uh, PainAway is an Australian-owned, Australian-made brand. It's number two in the topical, uh, health category. And we certainly believe by acquiring the brand and integrating into our business, um, we can certainly, uh, continue to drive revenue and growth, but also bring that new and unique innovation to the PainAway brand, uh, in our retailer partners.

On top of that, we're excited that we can take that brand into overseas markets, um, which is really important for us and also again, ensure that we continue that MPD development for our retailers, but also more importantly for consumers.  That paints a really exciting picture. Thanks for your time, Zack.

For more information about Wellnex and the investment opportunity, please click on the link in the description or reach out to us.